EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer
Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based […]